New Topical PDE4 Inhibitor Gets Green Light From FDA

(MedPage Today) — The FDA has approved the topical phosphodiesterase 4 (PDE4) inhibitor difamilast (Adquey) as a new option for mild/moderate atopic dermatitis (AD).
The approval allows for use in adults and pediatric patients at least 2 years…